Mutation status and immunohistochemical correlation of EGFR mutations in gastrointestinal stromal tumors

• Main Authors: Ozkayalar H, Ergoren MC, Tuncel G, Kurt S, Cevik E, Ozemri Sag S, Yilmaz Ozguven B, Kabukcuoglu F, Mocan G, Temel ŞG
• Format: Article
• Language: English
• Published: Sciendo 2021-07-01
• Series: Balkan Journal of Medical Genetics
• Subjects: epidermal growth factor receptor (egfr) gene; gastrointestinal stromal tumors (gists); targeted therapy
• Online Access: https://doi.org/10.2478/bjmg-2021-0006

Being one of the leading causes of cancer deaths worldwide and their resistance to conventional treatment methods, made gastrointestinal stromal tumors (GISTs) one of the hot topics in medical research areas in the past decade. To investigate molecular alterations underlying the tumor is of great importance to be able to develop new, targeted treatment options. In this study, GIST samples obtained from 40 Turkish patients were analyzed for actionable epidermal growth factor receptor (EGFR) mutations that are related to treatment regimes in non small cell lung cancer (NSCLC) to understand whether EGFR expression is altered in GISTs. Established alterations in EGFR can make the use of tyrosine kinase inhibitors possible, which are currently used in cancer therapy, especially in NSCLC. Our results indicated that EGFR mutations are rare in GISTs. Further research is needed to sequence whole coding regions of the gene to investigate new actionable mutations in EGFR in an increased sample size.